Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
45°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cue Biopharma, Inc.
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Updated Business Highlights
April 08, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Host Business Update Call and Webcast
April 02, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium
February 29, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit
November 22, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November
November 07, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
November 03, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Host Business Update Call and Webcast
November 02, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
September 27, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®
September 26, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
August 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Host Business Update Call and Webcast
August 02, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present at the Federation of Clinical Immunology Societies (FOCIS) 2023 Annual Meeting
June 14, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Host Investor Call
June 07, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present at the Jefferies 2023 Global Healthcare Conference
June 05, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Presents Positive Data Update from Ongoing Phase 1 Trials of CUE-101 for Recurrent/Metastatic HPV+ Head and Neck Squamous Cell Carcinoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 09, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
May 08, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Welcomes Seasoned Pharmaceutical Executive Pamela D. Garzone, Ph.D., to its Board of Directors
April 25, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Welcomes Industry Veteran Mr. Patrick Verheyen to its Board of Directors
April 12, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
March 21, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Host Business Update Call and Webcast
March 15, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present at Two March 2023 Investor Healthcare Conferences
March 01, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Enters into a Strategic Collaboration and Option Agreement with Ono Pharmaceutical for CUE-401
February 22, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma’s Therapeutic Immuno-STAT Biologics to be Featured in Oxford University Presentation at the 67th Biophysical Society Annual Meeting
February 16, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma Announces the Appointment of Dr. Rafi Ahmed to its Scientific Advisory Board
February 16, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Cue Biopharma to Present at Two February 2023 Scientific Conferences
February 01, 2023
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Tickers
CUE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.